News

A glimpse into the present and future of healthcare industry mergers and acquisitions

Surprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.

New analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.

Two presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.

AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.

IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.

Heart disease takes a heavy toll on the healthcare system, but promising new treatments are emerging

Here are the top ways to strengthen health information technology to advance value-based, quality care.

Health plans and PBMs that are reluctant to invest in mobile tools for their covered members will miss out.

F. Randy Vogenberg, PhD, partner, Access Market Intelligence, and cofounder National Institute of Collaborative Healthcare, Greenville, S.C., shares insight from AMCP.

At AMCP 2016, presenters identified five types of alternative payment models, and shared why pharmacists play a key role.

Value-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”

Kaveh Safavi, senior managing director for consulting firm Accenture’s global healthcare business, shares how payer mergers will affect provider payments.

AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching

: Providers and health plans aren’t the only industry groups affected by the shift to value-based care. It’s time for pharma to get in on the action.

An accurate account of your provider roster is essential to driving value-based care, according to one expert.

Study demonstrates how new technology can drive higher value healthcare for heart failure patients.

The generic metformin (Mallinkrodt) significantly reduced the risk of dying from heart attack and stroke compared to other common diabetes medications, according to a new study.

Greg Kennedy, research project manager with the ACO Research Team at the Dartmouth Institute for Healthcare Policy and Clinical Practice at Dartmouth College, shares recent ACO research findings.

A presenter at the AMCP Annual Meeting examines two different tools released by ASCO and NCCN and how a managed care organization utilizes these tools in the formulary review process.

Industry watchers weigh in on UnitedHealth Group’s announcement that it will exit all but a “handful” of state Affordable Care Act (ACA) exchanges.

At the AMCP Annual Meeting, three panelists shared real-world examples of technology that is improving patient engagement, adherence, and outcomes

At AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.

FDA took the unusual step of withdrawing approval of two cholesterol-lowering drugs late last week.

Republican presidential candidate Donald Trump recently unveiled his 7-point healthcare plan. Find out more.

At the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.

To achieve scale economies, large hospitals and healthcare systems should shift toward integrated organizations with standardized procedures and systematically reduced costs.